Do people with disabilities experience disparities in cancer care? A systematic review

Irene Tosetti[1]¶*, Hannah Kuper[2]¶

[1] M.Sc. Public Health, London School of Hygiene & Tropical Medicine, London, United Kingdom

https://orcid.org/0000-0001-5800-9153

[2] International Centre for Evidence in Disability, London School of Hygiene & Tropical Medicine, London, United Kingdom

https://orcid.org/0000-0002-8952-0023

* Corresponding Author

E-mail: Ionit5@student.london.ac.uk

Abstract

Background: Over 1.3 billion people, or 16% of the world's population, live with some form of disability. Recent studies have reported that patients with disabilities might not be receiving state-of-the-art treatment for cancer as their non-disabled peers; our objective was to systematically review this topic.

Methods: A systematic review was undertaken to compare cancer outcomes and quality of cancer care between adults with and without disabilities (NIHR Prospero register ID number: CRD42022281506). A search of the literature was performed in July 2022 across five databases: EMBASE, Medline, Cochrane Library, Web of Science and CINAHL databases. Peer-reviewed quantitative research articles, published in English from 2000 to 2022, with interventional or observational study designs, comparing cancer outcomes between a sample of patients with disabilities and a sample without disabilities were included. Studies were evaluated for risk of bias based on a set of criteria according to the SIGN 50 guidelines. A narrative synthesis was conducted according to the Cochrane SWiM guidelines, with tables summarizing study characteristics and outcomes. This research received no external funding.

Results: Thirty-one studies were included in the systematic review. Compared to people without disabilities, people with disabilities had worse cancer outcomes, in terms of poorer survival and higher overall and cancer-specific mortality. There was also evidence that people with disabilities received poorer quality cancer care, including: lower access to state-of-the-art care or curative-intent therapies, treatment delays, undertreatment or excessively invasive treatment, worse access to in-hospital services, less specialist healthcare utilization, less access to pain

medications and inadequate end-of-life quality of care.

Discussion: Limitations of this work include results from high-income countries only, exclusion of qualitative research, no meta-analysis and high risk of bias in 15% of included studies. In spite of these limitations, our results show that people with disabilities often experience severe disparities in cancer care: barriers at different levels must be eliminated to ensure that they receive equitable treatment.

Introduction

Cancer is a leading cause of death worldwide, resulting in nearly ten million deaths in 2020 according to WHO data.(1) In spite of this enormous burden of disease, late-stage presentation and lack of diagnosis and treatment remain common, leading to much higher mortality rates.(2) Each cancer type requires a different treatment regimen, so a correct diagnosis is essential to receiving the best treatment and reducing mortality.(3)(1) Good quality of care can also improve quality of life (e.g. through pain management), even when cure is no longer possible. Access to appropriate treatment is therefore of crucial importance, but inequalities in access have been observed for several groups, including people with disabilities.(4–10)

Over 1.3 billion people, or 16% of the world's population, live with some form of disability, according to the 2022 World Report on Disability. (11) This figure is expected to grow further in the coming decades, as the population ages and chronic health conditions increase globally. On average, people with disabilities are more likely to experience poor health, because of their underlying health condition/impairment and their socio-economically excluded position in society. (14,15) They also face a range of barriers to accessing care, including long waiting times, high costs, ableist discrimination by health professionals (12), inaccessible buildings, inconvenient locations, and lack of communication among different parts of the healthcare team. As a consequence, unmet healthcare needs are greater for people with disabilities, contributing towards poorer health and higher mortality. (11) This general pattern of disability-related healthcare exclusion is reflected in known disparities in the use of cancer prevention services, as people with disabilities have

lower cancer screening rates than those without disabilities. (13–18) This gap may also exist with respect to cancer care, as several studies have recently reported that patients with disabilities might not be receiving state-of-the-art treatment standards for their cancers (19–23). Furthermore, several studies suggest that cancer may be diagnosed at a later stage in patients with disabilities, and that they experience treatment disparities resulting in higher cancer-specific mortality rates. (24) Two recent scoping reviews found that patients with intellectual disabilities may be at risk of experiencing inequities at various points during cancer clinical pathways, (24) (25) but this issue has not been reviewed for people with disabilities more generally. Consequently, the aim of this study is to conduct a systematic literature review to compare cancer outcomes and quality of cancer care between adults with and without disabilities.

Materials and methods

A systematic review of the literature was conducted describing differences in cancer-related care between patients with and without disabilities, according to the PRISMA reporting guidelines; the study was recorded on the NIHR Prospero register of systematic reviews with ID number CRD42022281506 . (26,27)

Search Strategy

We used a systematic literature review to achieve our aim and objectives. The review was performed on July 1st 2022, across 5 databases: EMBASE, Medline, Cochrane Library, Web of Science and CINAHL databases. We included search terms on: disability (physical, sensory, psychological, communication and/or

cognitive disability; measured clinically or through self-report); and cancer treatment (surgery, radiotherapy, chemotherapy, palliative care for any type of cancer), limited to the past 22 years (2000-June 2022), and to English language. The full search strategy can be found in the supporting information S1 file.

Eligible studies included quantitative studies (observational or interventional), conducted in adults aged 18+, allowing comparison of cancer outcomes between people with disabilities (of any type) and those without disabilities. The disability definition had to be in agreement with the International Classification of Functioning, Disability and Health (ICF) framework (i.e. including impairment, activity limitations or participation restriction due to an underlying health condition in interaction with personal and environmental barriers).(28) Studies had to include one or more measures of outcomes along the cancer clinical pathway of diagnosis, treatment, and follow-up or end of-life care. Eligible outcomes were overall mortality after cancer diagnosis, cancer-related mortality, survival, access to state-of-the-art treatment (defined as intent-to-cure treatment when feasible or guideline-consistent stage-appropriate treatment), type of treatment received (medical vs surgical vs radiation vs. hormonal), invasiveness of treatment, delay of treatment, specialist care utilization, access to pain control prescription and end-of-life hospital use for palliative care. Studies focused on screening for cancer were not eligible, as this question was recently reviewed(29–35). There were no geographic restrictions.

Types of study excluded were editorials, commentaries, opinion papers, reviews, case reports, case series under 10 patients and conference abstracts. Studies with patients under age 18, studies without a measure of disability, studies that did not include a sample of patients with disabilities and a sample of patients without

disabilities and studies without outcome measures for cancer care were also excluded.

Study selection

All studies identified through the searches were exported to a Mendeley bibliographic database for deduplication and to Covidence software for screening. One author (IT) screened studies by title and abstract and full text to determine eligibility. Decisions to include were made according to inclusion criteria.

Data extraction and analysis:

A table was created for data extraction (Table 1 in Supplement1) listing authors, year of publishing, country where the study was undertaken, study design, type of cancer, type of disability, type of outcome, population size and overall risk of bias. One author (IT) extracted the data. A summary of study characteristics can be found in Table 1.

We also created a table with a summary of primary and secondary outcomes of each study (table 2); where possible, odds or prevalence ratios as a measure of association or *p*-values comparing measures in people with and without disabilities were extracted. Each study was also classified as “better”, “worse” or “null”, when outcomes respectively showed a better, worse or equal situation in quality of cancer care for people with disabilities in comparison to people without disabilities.

A narrative synthesis was conducted according to the Cochrane SWiM guidelines.

Determining risk of bias:

Studies were evaluated for risk of bias based on a set of criteria according to the SIGN 50 (Scottish Intercollegiate Guidelines Network) checklists as explained in Supplement 1. (36)

Overall Ratings were summarised as follows (figure 2) with RobVis tool:(37)

- Low risk of bias: all or almost all of the above criteria were fulfilled, and those that were not fulfilled were thought unlikely to alter the conclusions of the study;
- Medium risk of bias: some of the above criteria were fulfilled, and those not fulfilled were thought unlikely to alter the conclusions of the study;
- High risk of bias: few or no criteria were fulfilled, and those that were not fulfilled were thought likely or very likely to alter the conclusions of the study.

Ethical Considerations

Approval for the review was given by LSHTM MSc Ethics Board (internal ref. 26741). There were no ethical concerns for this literature review.

Financial support and Competing Interests

The Authors declare no competing interests; there are no known conflicts of interest associated with this publication and there has been no significant financial support for this work that could have influenced its outcome.

.

160

161

162

Results

The search was conducted on July 13th, 2022 resulting in 4140 titles identified (Fig 1). After removal of 408 duplicates, 3732 titles and abstracts were screened, and 3680 ineligible studies were excluded. Next, 52 full texts were retrieved and 21 were excluded because of ineligible study design, comparator, patient population, outcomes, intervention or setting. Finally, 31 studies were identified as eligible for the systematic review.



Figure 1. PRISMA Flowchart

Study Characteristics

Table 1 shows a summary of the characteristics of the 31 studies included in the systematic review. All the studies were conducted in high-income countries, with the greatest proportion coming from the USA (29% of the studies, n=9), followed by South Korea (19%, n=9), Japan (13%, n=4), France (10%, n=3), then by the UK, Netherlands and Sweden with two studies each, and by Belgium, Taiwan and Germany with one study each. Twenty studies (65%) were published after 2018, showing a marked growth in research interest on this topic in the past few years; only 11 eligible studies were published earlier, between 2000 and 2017.

A more detailed table of study characteristics is included in supplement 1.

193 Table 1. Summary of characteristics of included studies.

		N	%
REGION (as per WHO classification)	Western Pacific	14	45%
	European	11	36%
	Americas	9	29%
	African	0	0
	South East Asian	0	0
	Eastern Mediterranean	0	0
STUDY DESIGN	Retrospective cohort	27	87%
	Prospective cohort	3	10%
	Cross-sectional	1	3%
DISABILITY TYPE	Visual	0	0%
	Hearing	0	0%
	Physical	0	0%
	Intellectual-cognitive	9	29%
	Psychosocial	13	42%
	All types	9	29%
SAMPLE SIZE OF PEOPLE WITH DISABILITY	Smallest	46	n/a
	25th percentile	523	n/a
	Median	1016	n/a
	75th percentile	4077	n/a
TYPE OF CANCER	Any	7	23%
	Breast	9	29%
	Stomach and colorectal	4	13%
	Lung	3	10%
	Prostate	2	6%
	Others (Testicular, MM, AML, Bladder, Oral)	5	16%
	All types	1	3%
RISK OF BIAS	Low	12	39%
	Medium	14	45%
	High	5	16%

Table 2, Outcomes of studies

Study Design

Twenty-seven of the 31 studies used a retrospective cohort study design, with data either from a single center (n= 2) or from a national or multi-center health insurance and disability database (n=25), while three studies used a prospective cohort design, one from a single center and two from multi-center hospital networks. One study only used a cross-sectional design with a survey performed among patients of a network of cancer centers.

Types of Disabilities

Over a third of the eligible studies focused on people with psychosocial disability (42%, n=13) defined as a previous diagnosis of psychiatric or mental health issues. (38,39,41,44–53) Nine studies (29%, n=9) focused on intellectual, learning disabilities, cognitive impairment or dementia(40,42,54–60). Nine other studies (29%, n=9) considered all disability in general or grouped into subcategories (e.g. physical/communication/mental/internal organ/others). (19,22,23,43,61–65) Few studies differentiated by severity of impairment. (19,22,63,65,66)

Types of Cancer

Seven studies (23%) were about any type of malignancy, while almost a third (29%, n=9) were about breast cancer. There were 4 studies (13%) regarding stomach and colorectal malignancies, 3 (10%) on lung cancer, 2 (6%) on prostate cancer, and 1

216 study each for testicular, MM, AML, bladder and oral cancer. Finally, one study
217 included patients of breast, prostate and colorectal cancers (Table 1).

218

219 Types of outcome

220 The majority of papers (65%, n=20) included a measure of survival or mortality after
221 cancer diagnosis as primary or secondary outcome. Seventeen studies (55%)
222 included an outcome of access to state-of-the-art cancer treatment, measured as
223 type of treatment received (guidelines consistent according to disease stage) or
224 invasiveness of surgery or treatment delay. Four (13%) studies described access to
225 quality of end-of-life care, defined as access to appropriate pain control and end-of-
226 life hospital use for palliative care. One study included access to pain medications as
227 an outcome.

228

229 Risk of Bias

230 Almost half of the 31 studies (45%, n=14) had a medium risk of bias, mostly due to
231 possible misclassification bias for inclusion of people with disabilities based on
232 disability records (that have a tendency to miss mild cases) or missing data like
233 details about cancer treatment goals, behavioral factors or date of diagnosis, while
234 12 studies had a low risk of bias (39%, n=12). Finally, 5 papers were marked as
235 having a high risk of bias due to factors such as having a very small sample size, a
236 short follow-up, low data quality, a biased cohort or using a self-reporting survey. A
237 summary of the assessment of risk of bias, was created with RobVis tool (37) (Fig 2).



Figure 2. Risk of Bias (in alphabetic order)

D1=Selection bias D2=Information bias D3=Misclassification bias; D4=Confounding D5=Missing data;

Green=Low Yellow=Medium Red=High Made with Robvis tool(37)

Outcome Results

Outcomes are summarized in Table 2. Only one study found no difference in overall survival or disease-free survival between patients with and without disabilities. (39) Of note, it was a small study with a high risk of bias, with a cohort including only operable breast cancer in a small number of patients, and it still showed an association between disability and excessively invasive breast surgery without a valid clinical reason. The other 19 studies that included a measure of survival or mortality all showed, invariably, a direction of effect towards worse outcomes for people with disabilities; this was often worsened by the degree of severity of disability.(19,22,40,42,44) Among psychosocial disabilities, schizophrenia had generally the worst prognosis. (41,44,49,63,67) In studies that examined survival in cancer patients with all types of disability, there seemed to be far worse outcomes for those with severe disabilities and with intellectual impairment, with a large portion of that disparity not justifiable on the basis of rational clinical decisions. (19,22,65)

Table 2, Outcomes of studies

AUTHOR	PRIMARY OUTCOME	MEASURE IN people with disabilities	MEASURE IN PEOPLE WITHOUT DISABILITIES	EFFECT MEASURE	SECONDARY OUTCOME	MEASURE IN people with disabilities	MEASURE IN PEOPLE WITHOUT DISABILITIES	EFFECT MEASURE	TREND FOR people with disabilities
Afshar(54)	10-yr survival rate	77.6% (95% CI = 72.2–83.3%)	89.9% (95% CI = 89.4–90.3%)	10-yr survival relative rate: 12.3% lower for patients with disabilities	5-yr survival rate	84% (95% CI = 79.9–88.4%)	92.2% (95% CI = 91.8–92.5%)	5-yr survival relative rate: 8.2% lower for patients with disabilities	WORSE
Chang(52)	Access to state-of-the-art treatment	68% received surgery	82% received surgery	Adjusted OR of receiving surgery for patients with disabilities = 0.47 (95% CI = 0.34–0.65; P=0.001)	5-yr survival rate	50.50%	68.10%	Adjusted relative risk of death 1.58 higher for patients with disabilities (95% CI = 1.30–1.93; P,0.001).	WORSE
Cuypers(55)	Cancer-specific mortality	not mentioned	not mentioned	SMR= 1.48; (95% CI = 1.42-1.54) for people with disabilities	n/a	n/a	n/a	n/a	WORSE
Cuypers(68)	Insurance claims for cancer hospital care	IR = 28.9 per 1000 person/year	IR = 45.3 per 1000 person/year	IRR = 0.64 (95% CI = 0.62-0.66) in people with disabilities	n/a	n/a	n/a	n/a	WORSE
Fond(44)	End-of-life treatment access	Incidence of palliative in month before death = 81.3%	Incidence of palliative in month before death = 75.2%	more trips to palliative care in last month of life (aOR 1.32, 95%CI [1.15–1.51], p<0.001) in last month of life in people with disabilities	Overall survival time (days)	886	918	p value = 0.21	NULL for mortality, WORSE for end-of-life treatment
Fried(45)	Cancer-specific 5-yr mortality	not mentioned	not mentioned	HR = 1.39 (95% CI: 1.04-1.84) for patients with disabilities	Access to state-of-the-art treatment	12.8% received surgery	21.8% received surgery	OR = 0.66 (95% CI: 0.49-0.89) for pwd with disabilities of	WORSE

								receiving surgery	
Gross(43)	Screening results	not mentioned	not mentioned	PWD less often diagnosed for cancer through a mammography screening (OR for patients with physical impairment = 0.70; p < 0.05; OR for Sensory Impairment = 0.58; p < 0.05) than patients without disability.	Invasiveness of treatment	not mentioned	not mentioned	PWD less likely to receive breast conserving treatment (OR 0.58; p < 0.05) and more likely to have a mastectomy without reconstruction (OR = 1.96; p < 0.05) than those without disabilities	WORSE
Gupta(69)	Stage at diagnosis	8.4% diagnosed on autopsy or death certificate	1.9% diagnosed on autopsy or death certificate	aOR = 2.31 (95% CI 1.79–3.00) for PWD to have twice as likely to have colon cancer reported only after death (i.e., from autopsy or death certificate)	Access to state-of-the-art treatment	not mentioned	not mentioned	aOR =0.43 (95% CI 0.33–0.70) for pwd to receive surgery; aOR =0.21 (95% CI 0.13–0.36) for pwd to to receive adjuvant chemo	WORSE
Iezzoni(61)	Cancer-specific mortality	not mentioned	not mentioned	HR=1.37 (95% CI, 1.24 –1.51) of cancer specific mortality for people with disabilites	Access to state-of-the-art treatment	68.5% received surgery	82.2% received surgery	aRR 0.84 (95% CI 0.79-0.89) for pwd to receive surgery	WORSE

Iglay(47)	Treatment delay	8.60%	8.70%	ARR 1.36 (95% CI 1.06, 1.74) for pwd subgroup with severe mental illness of initial treatment delay at 60 days relative to controls	Diagnosis delay	34.90%	34.80%	ARR 1.11 (95% CI 1.00, 1.23) for pwd subgroup with comorbid anxiety and depression relative to controls	WORSE
Ishikawa(46)	Overall in-hospital mortality	4.20%	1.80%	OR = 1.35; (95% CI 1.04–1.75, P= 0.026) for pwd	Stage at diagnosis and access to state-of-the-art treatment	33.9% stage IV; 56.5% surgery	18.1% stage IV; 70.2% surgery	RR 1.86 (95% CI 1.72–2.00; P<0.001) of higher stage at diagnosis and OR = 0.77 (95% CI 0.69–0.85, P=0.001) for access to surgical or endoscopic treatment for pwd	WORSE
Kaneshiro(38)	Invasiveness of treatment	84.3% mastectomy	63.2% mastectomy	(P = 0.002)	Access to state-of-the-art treatment	56% received radiotherapy	75% received radiotherapy	(P = 0.078).	WORSE
Kashyap(48)	End of life Emergency Department use	15.6% with access to ED in last 30 days of life	13.3% with access to ED in last 30 days of life	p < 0.01	Impact of outpatient mental health treatment in mental illness	not mentioned	not mentioned	aOR 0.82 (95% confidence interval 0.78–0.87) for mental health patients on outpatient mental health treatment to have multiple end-of-life ED visits	WORSE
Kim(22)	Mortality	125.2 per 1000	104.3 per 1000	aHR=1.18 (95% CI: 1.14–1.21) for PWD and aHR = 1.62 (95% CI: 1.56–1.69) for severe disability group	Mortality in patients who received surgery	not mentioned	not mentioned	aHR 1.21 (95% CI: 1.16–1.27), even higher in severe disability group (aHR 1.69, 95% CI: 1.57–1.81),	WORSE

Kwon(19)	Median overall survival	36.8 months	51.2 months	p < 0.001	Access to state-of-the-art treatment	37.5% received transplant	43.7% received transplant	p=0.072	WORSE
Kwon(65)	Median overall survival	10.8 months	17.1 months	p=0.02	Access to state-of-the-art treatment	chemo 71.2% vs 77.1%, P = .0031, and transplant 17.5%	chemo 77.1%; transplant 26.9%	p = 0.0031 and p=0.002	WORSE
Lawrence(53)	All-cause and cancer-specific mortality	not mentioned	not mentioned	all-cause mortality HR=1.36; (95% CI 1.18, 1.57) and cancer-specific mortality HR=1.21 (95% CI 1.03, 1.44) for women with SMI compared to controls	10-year overall survival	73.10%	78.30%	not mentioned	WORSE
Libert(40)	Overall mortality	12.3% at 2 years	2% at 2 years	HR = 6.13 (95% CI = 2.07–18.09; p = 0.001) for people with cognitive impairment; HR = 3.06; (95% CI = 1.31–7.11, p=0.009) for people with loss of instrumental autonomy	n/a	n/a	n/a	n/a	WORSE
Mahabaleshwarkar(50)	Access to state-of-the-art treatment	not mentioned	not mentioned	aOR= 0.79 (95% CI= 0.65–0.97) of receiving guideline-consistent breast cancer treatment for pwd	Healthcare utilization	not mentioned	not mentioned	AIRR = 0.92 (95% CI = 0.89–0.94) for breast-cancer related outpatient visits; AIRR = 0.84 (95% CI = 0.71– 0.99) for breast-cancer	WORSE

								related ER visits for pwd	
Martin(42)	Overall mortality	not mentioned	not mentioned	HR 1.39 (95% CI =1.09, 1.78, p>0.01) for people with disabilities	Access to state-of-the-art treatment	22.3% with mild, 35.6% with moderate and 51.8% with severe cognitive impairment received primary endocrine therapy (NOT state of the art)	12.4% women with normal cognition received PET	p <0.001	WORSE
Park(64)	Long-term all-cause mortality of 5-year cancer survivors	not mentioned	not mentioned	Male Pwd HR = 1.48 (95% CI 1.33–1.66) and female Pwd HR= 1.53 (95% CI, 1.28–1.83) compared with controls	Short-term (<5 years) all-cause mortality	not mentioned	not mentioned	male with impaired communication HR= 1.24 (95% CI, 1.07–1.44), female with internal organ disability HR, 2.20 (95% CI, 1.42–3.42)	WORSE
Robb(57)	Median overall survival	23.0 months (0.2–140.7 months)	72.6 months for controls (0.9–135.5 months)	p < 0.001	n/a	n/a	n/a	n/a	WORSE
Sathianathen(67)	Access to state-of-the-art treatment	not mentioned	not mentioned	OR 0.55 (95% CI 0.37–0.81) for patiens with severe mental illness and OR 0.71 (95%CI 0.58–0.88) for those with depression of receiving	Cancer-specific mortality	not mentioned	not mentioned	severe mental illness pts had HR 1.35 (95% CI1.14–1.61) in both the NMIBC (HR 1.48, 95% CI 115–1.92) and MIBC (HR1.37, 95% CI 1.10–1.72) subgroups,	WORSE

				curative treatment.				compared with controls	
Sato(62)	Access to state-of-the-art treatment	not mentioned	not mentioned	difference not significant	n/a	n/a	n/a	n/a	NULL
Segerlantz(59)	Pain control prescription	36%	60%	RR 0.61 (95% CI 0.54-0.69) for pwd to have prescription of COX inhibitors, RR 0.63 (95% CI 0.53-0.73) for weak opioids	Prescription of other drugs	36% on antidepressants ; 47% on anxiolytics	17% on antidepressants ; 16% on anxiolytics	RR 2.09 (95% CI 1.74–2.51) for pwd to be prescribed antidepressants : RR 2.84 (2.39–3.38) for pwd to be prescribed anxiolytics	WORSE
Segerlantz(58)	Healthcare utilization	1.5 visits per person in final year of life	1.75 visits per person in final year of life	RR 0.90 (95% CI 0.87–0.93) for pwd to be less likely than controls to have >1 visit in specialist inpatient care during last year of life;	Quality of end-of-life care	31% accessed advanced hospital care	55% accessed advanced hospital care	RR 0.57 (95%CI 0.51–0.64) for pwd to have access to advanced hospital care	WORSE
Shin(70)	Overall mortality	531.2 per 1000	463.1 per 1000	aHR 1.08, (95% CI: 1.06–1.11) for pwd, and subgroup with severe disability HR =1.20 (95% CI: 1.16–1.24)	Access to state-of-the-art treatment	19.8% surgery; 42.3% chemo; 26.4% radiation	21.9% surgery; 46.1 chemo; 27.6% radiation	aOR Surgery= 0.82, (95% CI 0.77–0.86), aOR chemo =0.80, (95% CI: 0.77–0.84), aOR radiotherapy =0.92 (95% CI: 0.88–0.96) for pwd	WORSE

Shin(63)	Access to state-of-the-art treatment	Surgery 33.1% ; ADT 57.9%	Surgery 38.6%; ADT 55%	Surgery aOR=0.79, (95% CI 0.74-0.84); ADT aOR =1.10 (95% CI1.04-1.16) for pwd. For severe disability, surgery aOR= 0.60 (95% CI, 0.54-0.67), ADT aOR=1.29 (95% CI, 1.18-1.42)	Overall mortality and cancer-specific mortality	57.3 per 1000; 26.7 per 1000	43.7 per 1000; 21.7 per 1000	Overall mortality aHR, 1.20 (95% CI, 1.15-1-25) for pwd; with severe disability aHR 1.47 (95% CI 1.37-1.57). Cancer-specific mortality aHR 1.11 for pwd (1.04-1.18), but no difference when pwd had same access to surgery.	WORSE
Shinden(39)	Access to state-of-the-art treatment	total mastectomy 78%, postoperative adjuvant chemo 0%, radiation 2%	total mastectomy: 59%; postop adjuvant chemo 19%; radiation 18%	p <0.05 for all the mentioned outcomes	Overall survival	not mentioned	not mentioned	no difference	NULL for mortality, WORSE for treatment
Tran(41)	Overall mortality and All-cancer-mortality	not mentioned	not mentioned	4-fold higher all-cause mortality for schizophrenia. Cancer SMR = 1.5 (95% CI: 1.2-1.9).	Mortality by cancer type	not mentioned	not mentioned	men with pwd and lung SMR = 2.2 (95% CI, 1.6-3.3); women with pwd and breast SMR = 2.8 (95% CI, 1.6-4.9) compared to controls	WORSE

Viprey(49)	Access to state-of-the-art treatment	early palliative care: 77%; end-of-life chemo: 10%; end of life surgery: 17%	early palliative care: 72%; end-of-life chemo: 15%; end of life surgery: 20%	aOR for early palliative care= 1.27 (95% CI=1.03;1.56; p=0.04) , aOR for end-of-life chemo=0.53 (0.41-0.70, p<0.0001), aOR end-of-life surgery =0.73 (0.59;0.90, p<0.01) for pwd.	Quality of end-of-life care	Hospitalization in acute care unit the month before death 33%; median length of last hospital stay 13 days; deaths in the ICU/ED 10%	Hospitalization in acute care unit the month before death 24%; median length of last hospital stay 10 days; deaths in the ICU/ED 11%	aOR for hospitalization in acute care unit the month before death = 1.41 (95% CI=1.18;1.67; p<0.001); longer length of last hospital stay (Beta=1.22, SD=0.05; p<0.0001); aOR for deaths in the ICU/ED = 0.74 (95% CI = 0.56;0.97; p = 0.04) for pwd.	WORSE

There were 16 studies showing lower chance in receiving state-of-the-art cancer treatment for people with disabilities. Only one study showed no difference. (62) However, it had a high risk of bias since the incidence of disability in its retrospective cohort was inexplicably only half of the known national incidence, suggesting severe misclassification bias, and data about gender and degree of disability was missing. The studies showed that cancer treatment was suboptimal for people for disabilities in many ways, but in particular a lower likelihood of undergoing guideline-consistent surgery when indicated. (22,23,50,52,60,61,63,67) Several studies showed that when people with disabilities were correctly treated with guideline-consistent surgery, their mortality was similar or only slightly higher than controls. (61,63) This finding suggests that differences in frequency of appropriate treatment appear to explain the higher cancer-specific mortality for this vulnerable population, with higher mortality likely due to loss of chance and unequal clinical care. People with disabilities were also more likely to face diagnosis and treatment delays (22,45,46,55,56,71) – but not when access to screening was optimal, (38) underlining the importance of good screening access. People with disabilities were also less likely to receive curative-intent transplants for blood cancers (19,65), and more likely to receive inappropriate radical mastectomy instead of guideline-consistent minimally invasive procedures for breast cancer.(39,42,43)

As for end-of-life and palliative care, 4 studies (44,48,49,58) showed a direction of effect towards worse outcomes for people with disabilities. One of this studies, with low risk of bias, (48) showed an association between receiving outpatient treatment from a mental health professional and having less end-of-life ED visits, suggesting the importance of access to mental health services to improve end-of-life care. One

study showed an association between disability and worse access to prescriptions for pain treatment during cancer care, a situation likely to severely compromise quality of life. (59) Finally, a study (58)reported that patients over age 55 with intellectual disability were more likely than controls to have worse access to specialist care in the last year of life. In this study, most of the disabled patients died in their own homes or group homes with scarce staffing, suggesting a lack of adequate end-of-life assistance and likely unaddressed distressing symptoms.

Regarding what other factors might be contributing to worse outcomes, one study (55) showed an association between worse access to screening programs for breast, colon and cervix cancers and higher cancer specific mortality, underlining the inequality in screening practices. Two other studies highlighted an association between barriers to screening and worse outcomes for gastric (22) and breast (38) cancer in people with disabilities. Two studies detected even worse disparities in access to state-of-the-art treatment or end-of-life care related to ethnicity and age, (48,61) with young disabled non-white men having the worst outcomes. One study of people with intellectual disabilities with any type of cancer suggested worse underdiagnosis for older females, (56) while another focusing on breast cancer detected an association between physical disability and inappropriate invasiveness of treatment (72). In a study of non-small cell lung cancer patients, (61) those with respiratory or nervous system disabilities had the lowest chance of receiving guideline-appropriate surgery, while another paper on lung cancer recorded the worst access to treatment among people with communication or neurologic disabilities. (23) A study about stomach cancer and patients with all kinds of disabilities also found an association between worse outcomes and severe intellectual impairment. (22)

309 Finally, three studies showed an association between worse outcomes of treatment
310 access and poverty among people with cancer. (65)(19)(48)

311

312 Discussion

313 In our review, compared to people without disabilities, people with disabilities were
314 found to have worse survival, higher overall and cancer-specific mortality, loss of
315 chance for access to state-of-the-art care or curative-intent therapies, treatment
316 delays, undertreatment or excessively invasive treatment, worse access to in-
317 hospital services, less specialist healthcare utilization, more difficult access to pain
318 medications and inadequate end-of-life quality of care. Even if sometimes treatment
319 decisions for people with disabilities can be clinically complex, such as the above-
320 mentioned case of cognitive impairment with legal consent or non-compliance
321 issues, or when confronted with a disability-related shortened life expectancy or
322 frailty for some syndromes(25), there is no plausible medical justification for such a
323 wide disparity compared to patients without disabilities, and these results raise
324 severe concerns about equality in cancer care.(74)

325 The results of this study are consistent with those of other recent literature reviews
326 (12,24,25,73), showing that people with disabilities experience inequities at several
327 points throughout the cancer care pathway. Screening disparities have been known
328 and documented for years: they can vary by disability type, severity, healthcare offer
329 and social or demographic situations, with some differences across countries, but
330 globally there is a largely similar trend of major barriers to screening for people with

disability, (12) showing a clear need to improve the inclusiveness of these early-diagnosis services.(73)

Providing equitable cancer care has to start early in the cancer clinical pathway, because delays in receiving a diagnosis tend to lead to late access to treatment and worse outcomes.(74) A frequently observed issue is that new signs and symptoms tend to be attributed to often to the underlying disability, a clinical mistake called "diagnostic overshadowing"(75). A recent scoping review about cancer outcomes in adults with intellectual and developmental disabilities has described disparities at every step of the way, from screening, to staging, to treatment and survival outcomes, recognizing how these experiences do not originate simply from a gap in early diagnosis, but from larger structural issues that ultimately hinders quality of the entire cancer care pathway. (76) Another review of cancer treatments for people with intellectual disabilities highlighted possible themes that might interfere with treatment, such as genetic syndrome frailty that might render certain drug treatments too dangerous, the issue of behavioral non-compliance in a subgroup of patients, and problems related to legal capacity and obtainment of informed consent. Still, these three factors should not represent an insurmountable barrier because with appropriate arrangements (e.g. pharmacology consults, procedural sedation, legal assistance) it should still be possible to offer guideline-consistent treatment to patients.(25) With physical disabilities clinical decisions can sometimes be objectively more difficult than in people without disabilities, because of concerns about baseline performance status or competing health risks due to invasive or toxic treatments that might result in further dramatic loss of function (e.g. possible loss of post-operative upper limb function after breast surgery in patients with previous spinal cord injury and lower limb paralysis); this has been described as a compelling

356 reason to move towards better cooperation between cancer care clinicians and
357 disability specialists who have been in charge of the patient well before their
358 oncology episode, and also as one of the fundamental reasons that make shared
359 decision making with patients (or sometimes their families or caregivers) of the
360 utmost importance.(12)

361 This clear evidence of inequities emphasizes the very urgent need for better cancer
362 care for people with disabilities. Furthermore, disparity in healthcare for people with
363 disabilities is not unique to oncology, (77) as research about the recent Covid-19
364 pandemic has clearly proven. (78–82) During the pandemic, people with disabilities
365 have died in disproportionate numbers – almost three times as much globally than
366 people without disabilities -(83) and have been excluded from the decision-making
367 process, because their needs have been ignored; they have ended up facing an
368 increasing amount of psychological distress, lack of social support, extreme isolation,
369 food insecurity, disparities in health care access and even discrimination at work. In
370 many cases, government response has compromised the human rights of disabled
371 people, having exposed and magnified existing structural failings and
372 inequalities.(84)

373 Recently, the second report of the Missing Billion Initiative has called for reimagining
374 health systems with a vision of inclusive health informed by diverse perspectives of
375 people with disabilities, who are still facing worse health outcomes across SDG3
376 indicators (Sustainable Development Goal 3 by the WHO, i.e. ensure healthy lives
377 and promote well-being for all at all ages), globally and with all sort of impairment
378 types. (85) The first Missing Billion report had highlighted a substantial life
379 expectancy gap of 10-20 years for people with disabilities, with all-cause mortality

380 rates approximately twice as high as those of people without disabilities.(83)
381 Closing this gap is now a priority, but it requires long-term investments to design
382 from the start health systems that expect, accept and connect people with
383 disabilities, with sufficient earmarked funds, dedicated leadership and clear
384 governance based on data and evidence disaggregated by disability. Ideally
385 service delivery should aim at affordability, autonomy of patients, accessibility,
386 specific workforce skillsets and availability of rehabilitation services. (85) The
387 multiple barriers experienced by people with disabilities during their cancer care (Fig
388 3) are hence a reflection of a broader process of discrimination and disadvantage,
389 (86) mirrored in structural failings of current healthcare systems, within networks of
390 intersecting factors that ultimately influence cancer outcomes. (24)

391

392 **Figure 3: Barriers experienced by people with disabilities during cancer care**

393

Healthcare workers need to receive evidence-based and appropriate training about disabilities, directly involving people with disabilities and using a monitoring system to measure cultural progress and outcome improvement. This could help foster a change to move away from the ableist attitudes that are too often still observed, contributing to wrong assumptions and subsequent mistakes of diagnostic overshadowing or failure to anticipate specific complications (12,87). In a very recent qualitative study from the USA, (88) interviewed physicians, mostly middle-aged white males, felt inadequately reimbursed for accommodations required by the 1990 Americans with Disabilities Act; according to some of these doctors, these concerns simply led them to discharge patients with disabilities. Many physicians openly spoke about the lack of accessibility in their clinics without any plans to improve it, and

406 several demonstrated a complete lack of disability knowledge about how to manage
407 very basic issues – even stating that they were regularly sending patients to a zoo,
408 cattle processing plant or supermarket to obtain a weight if a patient was in a
409 wheelchair and unable to stand; several doctors admitted that they rarely spoke to
410 these patients, regardless of the patients' ability to communicate, and that
411 information was almost exclusively obtained from the caregiver. This confirms
412 findings from previous qualitative research, (10) that had described a lack of skills by
413 healthcare workers to feel empathy for the embodied experience of living with a
414 disability, with an obstinate resistance to adapting their habitual practice to these
415 patients.

416 The importance of inclusive clinical trials to close the evidence gap about what works
417 to improve cancer care for people with disabilities cannot be overemphasized (89).
418 There is still too little evidence about how to treat cancer in the population with
419 disabilities, which is very diverse and can have widely different therapeutic needs
420 (hence existing services must be offered in a flexible, respectful, inclusive and
421 accessible way to be relevant for this patient population). Thus it is of the utmost
422 importance to enrol people with disabilities in clinical trials in oncology - both for
423 curative-intent interventions and for palliative treatments; yet, historically they have
424 been left out of studies, due to many factors such as ableist prejudice, or multiple
425 barriers such as accessibility of research facilities and access to transportation, or
426 lack of caregivers' engagement. (90,91) Unfortunately, in clinical trials pre-existing
427 conditions are often excluded, even if the conditions have little bearing on the
428 treatment being tested or the outcome of the trial. Excluding disabled individuals
429 from a study can result in a study population that does not even represent the
430 general population, since disability often correlates with other inequalities (such as

poverty and unemployment). The importance of targeting the recruitment of disabled individuals into clinical trials, as well as considering the unique barriers and motivations of this population, needs to be highlighted. A person with a disability may have difficulty traveling to a trial site; moreover, healthcare organizations should consider their audiences' digital literacy and the accessibility of their communications. Funds should be allocated to improve healthcare communication, adapting multiple formats, using captions and alt-text or pictorial representations of concepts as appropriate for the specific context. In addition, disabled individuals appear to be underrepresented as investigators in scientific research.(92) Despite 19% of the UK's general population identifying as disabled, only 4% of academic, research, and teaching staff do. Even if 25% of American adults live with a disability, in 2020 only 4% of US STEM PhDs were awarded to people with impaired hearing or vision, and just 1% to people with a mobility limitation. More disability-confident schemes and unconscious bias training could at least partially mitigate hiring discrimination, creating an academic workforce that better reflects the community in which it is based.(93)

Physicians and people with disabilities should be able to collaborate along care pathways with shared-decision making, an approach based not only on clinical technical advice but on the life experience of patients, their caregivers and families, according to the principle of “Nothing About Us Without Us”.(12) In the clinical setting, barriers in physical access should be removed to avoid unacceptable delays in diagnosis and treatment.(94)(10) Barriers in communication should be eliminated at several levels, from overcoming communication obstacles (not only for the hearing or visually impaired patients, but also with special-needs assistance for intellectual disability), to improving education of patients, clinicians and caregivers about cancer

456 and the importance of screening, to training healthcare workers about the emotional
457 and physical needs of people with disabilities, (95) enhancing cooperation with other
458 specialists caring for them, in cross-functional teams, to anticipate and possibly
459 reduce the impact of complications, with the goal of a patient-centred pathway.

460 The strengths of this study include having followed PRISMA and ICM50 guidelines
461 for systematic reviews; furthermore, the search strategy was based on a list of
462 proven disability-specific terms and applied to the five largest medical databases
463 analysing a twenty-year span of publications. This work has some limitations: firstly,
464 the search strategy, limited to five databases and to English language only, might not
465 be fully comprehensive. Secondly, all the eligible papers were from high-income
466 countries, limiting the generalizability of the results, even if there is no reason why
467 the situation should be very different in low and middle-income countries. Thirdly, no
468 qualitative papers or grey literature were included in the search strategy, hence the
469 views and opinions of people with disabilities about their cancer care were not
470 investigated. Finally, the findings were very diverse hence it was not possible to
471 conduct a meta-analysis, and approximately 15% of the studies had a high risk of
472 bias.

473 In conclusion, people with disabilities often experience severe disparities in cancer
474 care compared to people without disabilities; physical and cultural barriers at
475 different levels must be eliminated to ensure they receive equitable care. There is an
476 urgent need for a robust health policy effort by governments, reimagining health
477 systems with a vision of inclusive health and a sustained commitment, building on
478 decades of progress on disability rights and engaging the participation of people with
479 disabilities at all levels.

Acknowledgments

I.T. would like to thank Danae Rodriguez Gatta, for assistance with disability search terms, and Dr. Meena Cherian, for many fruitful discussions about health systems and development goals.

References

1. World Health Organisation. Cancer Fact Sheet [Internet]. 2022 [cited 2022 Apr 13]. Available from: https://www.who.int/news-room/fact-sheets/detail/cancer

2. WHO, International Agency for Research on Cancer. Globocan 2020 - Incidence and mortality statistics (all cancers excl. non-melanoma skin cancer). 2020.

3. WHO. Cancer - Screening and early detection [Internet]. [cited 2022 Oct 30]. Available from: https://www.who.int/europe/news-room/fact-sheets/item/cancer-screening-and-early-detection-of-cancer

4. Olusola P, Banerjee HN, Philley J V., Dasgupta S. Human Papilloma Virus-Associated Cervical Cancer and Health Disparities. Cells. 2019 Jun 21;8(6):622.

5. Manz CR, Odayar VS, Schrag D. Disparities in cancer prevalence, incidence, and mortality for incarcerated and formerly incarcerated patients: A scoping review. Cancer Med. 2021 Oct 1;10(20):7277–88.

6. Williams AD, Buckley M, Ciocca RM, Sabol JL, Larson SL, Carp NZ. Racial and socioeconomic disparities in breast cancer diagnosis and mortality in Pennsylvania. Breast Cancer Res Treat. 2022 Feb 1;192(1):191–200.

7. Lee RJ, Madan RA, Kim J, Posadas EM, Yu EY. Disparities in Cancer Care and the Asian American Population. Oncologist. 2021 Jun 1;26(6):453–60.

504 8. Davies A, Gurney J, Garvey G, Diaz A, Segelov E. Cancer care disparities among
505 Australian and Aotearoa New Zealand Indigenous peoples. Curr Opin Support Palliat
506 Care. 2021 Sep 1;15(3):162–8.

507 9. Ellis L, Canchola AJ, Spiegel D, Ladabaum U, Haile R, Gomez SL. Racial and Ethnic
508 Disparities in Cancer Survival: The Contribution of Tumor, Sociodemographic,
509 Institutional, and Neighborhood Characteristics. J Clin Oncol. 2018 Jan 1;36(1):25–
510 33.

511 10. Sakellariou D, Anstey S, Gaze S, Girt E, Kelly D, Moore B, et al. Barriers to accessing
512 cancer services for adults with physical disabilities in England and Wales: an
513 interview-based study. BMJ Open. 2019;9(6):e027555.

514 11. WHO. Global report on health equity for persons with disabilities [Internet]. World
515 Health Organization., editor. WHO; 2021 [cited 2023 Feb 19]. Available from:
516 https://www.who.int/publications/i/item/9789240063600

517 12. Iezzoni LI. Cancer detection, diagnosis, and treatment for adults with disabilities.
518 Lancet Oncol. 2022 Apr 1;23(4):e164–73.

519 13. Steele CB, Townsend JS, Courtney-Long EA, Young M. Prevalence of Cancer
520 Screening Among Adults With Disabilities, United States, 2013. Prev Chronic Dis.
521 2017 Jan;14:E09.

522 14. Horner-Johnson W, Dobbertin K, Iezzoni LI. Disparities in receipt of breast and
523 cervical cancer screening for rural women age 18 to 64 with disabilities. Womens
524 Health Issues. 2015;25(3):246–53.

525 15. Abrams MT, Myers CS, Feldman SM, Boddie-Willis C, Park J, McMahon RP, et al.
526 Cervical cancer screening and acute care visits among Medicaid enrollees with
527 mental and substance use disorders. Psychiatr Serv. 2012 Aug 1;63(8):815–22.

528 16. Kim YJ, Shin DW, Kim HW, Jung JH, Han K, Cho IY, et al. Disparities in gastric
529 cancer screening among people with disabilities: a national registry-linkage study in
530 South Korea. Gastric Cancer. 2020 May 1;23(3):497–509.

531 17. Horner-Johnson W, Dobbertin K, Andresen EM, Iezzoni LI. Breast and cervical cancer
532 screening disparities associated with disability severity. Women's Health Issues. 2014
533 Jan;24(1).

534 18. Courtney-Long E, Armour B, Frammartino B, Miller J. Factors associated with self-
535 reported mammography use for women with and women without a disability. J
536 Womens Health (Larchmt). 2011 Sep 1;20(9):1279–86.

537 19. Kwon J, Kim SY, Yeob KE, Han HS, Lee KH, Shin DW, et al. The Effect of Disability
538 on the Diagnosis and Treatment of Multiple Myeloma in Korea: A National Cohort
539 Study. Cancer Res Treat. 2020 Jan;52(1):1–9.

540 20. Bergamo C, Sigel K, Mhango G, Kale M, Wisnivesky JP. Inequalities in lung cancer
541 care of elderly patients with schizophrenia: an observational cohort study. Psychosom
542 Med. 2014;76(3):215–20.

543 21. Huang HK, Wang YW, Hsieh JG, Hsieh CJ. Disparity of end-of-life care in cancer
544 patients with and without schizophrenia: A nationwide population-based cohort study.
545 Schizophr Res. 2018;195:434–40.

546 22. Kim HW, Shin DW, Yeob KE, Cho IY, Kim SY, Park SM, et al. Disparities in the
547 diagnosis and treatment of gastric cancer in relation to disabilities. Clin Transl
548 Gastroenterol. 2020 Oct 1;11(10):1–12.

549 23. Shin DW, Cho JH, Noh JM, Han H, Han K, Park SH, et al. Disparities in the Diagnosis
550 and Treatment of Lung Cancer among People with Disabilities. J Thorac Oncol. 2019
551 Feb;14(2):163–75.

552 24. M S, A A, H OK, J H, S S, C K, et al. A scoping review documenting cancer outcomes
553 and inequities for adults living with intellectual and/or developmental disabilities. Eur J
554 Oncol Nurs. 2021 Oct;54:102011.

555 25. Boonman AJ, Cuypers M, Leusink GL, Naaldenberg J, Bloemendal HJ. Cancer
556 treatment and decision making in individuals with intellectual disabilities: a scoping
557 literature review. Lancet Oncol. 2022 Apr;23(4):e174–83.

558 26. Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The
559 PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ
560 [Internet]. 2021 Mar 29 [cited 2023 Feb 19];372. Available from:
561 https://www.bmj.com/content/372/bmj.n71

562 27. Tosetti I, Kuper H.
563 https://www.crd.york.ac.uk/prospero/display_record.php?RecordID=281506. 2022.

564 28. International Classification of Functioning, Disability and Health (ICF) [Internet]. [cited
565 2022 Oct 20]. Available from:
566 https://www.who.int/standards/classifications/international-classification-of-
567 functioning-disability-and-health

568 29. Iezzoni LI, Rao SR, Agaronnik ND, El-Jawahri A. Associations between Disability and
569 Breast or Cervical Cancers, Accounting for Screening Disparities. Med Care. 2021
570 Feb 1;59(2):139–47.

571 30. Andresen EM, Peterson-Besse JJ, Krahn GL, Walsh ES, Horner-Johnson W, Iezzoni
572 LI. Pap, mammography, and clinical breast examination screening among women
573 with disabilities: A systematic review. Women's Health Issues. 2013 Jul;23(4).

574 31. A systematic review of the barriers and facilitators influencing the cancer screening
575 behaviour among people with intellectual disabilities - ScienceDirect [Internet]. [cited
576 2023 Feb 19]. Available from:
577 https://www.sciencedirect.com/science/article/abs/pii/S1877782121002010

578 32. Connolly J. Barriers to access to cancer screening for people with learning disabilities:
579 a review. The Lancet. 2013 Nov;382:S29.

580 33. Andiwijaya FR, Davey C, Bessame K, Ndong A, Kuper H. Disability and Participation
581 in Breast and Cervical Cancer Screening: A Systematic Review and Meta-Analysis.
582 Int J Environ Res Public Health. 2022 Aug 1;19(15).

583 34. Chan DNS, Law BMH, Au DWH, So WKW, Fan N. A systematic review of the barriers
584 and facilitators influencing the cancer screening behaviour among people with
585 intellectual disabilities. Cancer Epidemiol. 2022 Feb 1;76:102084.

586 35. Steele CB, Townsend JS, Courtney-Long EA, Young M. Prevalence of Cancer
587 Screening Among Adults With Disabilities, United States, 2013. Prev Chronic Dis.
588 2019;14.

589 36. Healthcare Improvement Scotland. SIGN 50. 2011;

590 37. McGuinness LA, Higgins JPT. Risk-of-bias VISualization (robvis): An R package and
591 Shiny web app for visualizing risk-of-bias assessments. Res Synth Methods. 2021
592 Jan 1;12(1):55–61.

593 38. K. K, M. K, M. T, M. Y, Y. S, M. K, et al. Current Status and Problems of Breast
594 Cancer Treatment with Schizophrenia. Clin Breast Cancer. 2022;22(4):e399–406.

595 39. Shinden Y, Kijima Y, Hirata M, Nakajo A, Tanoue K, Arigami T, et al. Clinical
596 characteristics of breast cancer patients with mental disorders. Breast. 2017
597 Dec;36:39–43.

598 40. Slachmuylder JL, Libert Y, Dubruille S, Borghgraef C, Merckaert I, Paesmans M, et al.
599 Vulnerabilities in older patients when cancer treatment is initiated: Does a cognitive
600 impairment impact the two-year survival? PLoS One. 2016;11(8):e0159734.

601 41. Tran E, Rouillon F, Loze JY, Casadebaig F, Philippe A, Vitry F, et al. Cancer mortality
602 in patients with schizophrenia: an 11-year prospective cohort study. Cancer.
603 2009;115(15):3555–62.

604 42. C. M, A. S, J. M, M. B, E. H, M. B, et al. Treatment choices for older women with
605 primary operable breast cancer and cognitive impairment: Results from a prospective,
606 multicentre cohort study. J Geriatr Oncol. 2021;12(5):705–13.

607 43. Gross SE, Pfaff H, Swora M, Ansmann L, Albert US, Gross-Kunkel A. Health
608 disparities among breast cancer patients with/without disabilities in Germany. Disabil
609 Health J. 2020;13(2).

610 44. Baumstarck K, Viprey M, Auquier P, Fond G, Pauly V, Duba A, et al. End of life breast
611 cancer care in women with severe mental illnesses. Sci Rep. 2021;11(1):10167.

612 45. D.A. F, H. SN, D. G, S. Z, W. H, S.H. G, et al. Impact of serious mental illness on the
613 treatment and mortality of older patients with locoregional high-grade (nonmetastatic)
614 prostate cancer: retrospective cohort analysis of 49 985 SEER-Medicare patients
615 diagnosed between 2006 and 2013. Cancer Med. 2019;8(5):2612–22.

616 46. H. I, H. Y, H. M, K. F. Differences in cancer stage, treatment and in-hospital mortality
617 between patients with and without schizophrenia: Retrospective matched-pair cohort
618 study. British Journal of Psychiatry. 2016;208(3):239–44.

619 47. Iglay K, Santorelli ML, Rhoads GG, Demissie K, Hirshfield KM, Williams JM, et al.
620 Diagnosis and treatment delays among elderly breast cancer patients with pre-
621 existing mental illness. Breast Cancer Res Treat. 2017;166(1):267–75.

622 48. M. K, J.P. H, D.T. C, Pollom E.L. AO - Kashyap Daniel T.; ORCID:
623 http://orcid.org/0000-0003-2760-1554 AO - Pollom, Erqi L.; ORCID:
624 http://orcid.org/0000-0003-2908-6293 AO - Harris, Jeremy P.; ORCID:
625 http://orcid.org/0000-0001-7603-0263 MO http://orcid. org/0000 0002 7336 1056
626 AOC. Impact of mental illness on end-of-life emergency department use in elderly
627 patients with gastrointestinal malignancies. Cancer Med. 2021;10(6):2035–44.

628 49. M. V, V. P, S. S, K. B, V. O, P.-M. L, et al. Palliative and high-intensity end-of-life care
629 in schizophrenia patients with lung cancer: results from a French national population-
630 based study. Eur Arch Psychiatry Clin Neurosci. 2021;271(8):1571–8.

631 50. R. M, R. K, B. B, D. WS, Y. Y. Impact of preexisting mental illnesses on receipt of
632 guideline-consistent breast cancer treatment and health care utilization. Popul Health
633 Manag. 2015;18(6):449–58.

634 51. N.J. S, Y. F, S.L. J, I. K, C.J. W, S. V, et al. Disparities in Bladder Cancer Treatment
635 and Survival Amongst Elderly Patients with a Pre-existing Mental Illness. Eur Urol
636 Focus. 2020;6(6):1180–7.

637 52. T.-S. C, S.-J. H, Y.-C. S, L.-F. C, H.-C. H, M.-S. L, et al. Disparities in Oral Cancer
638 Survival among Mentally Ill Patients. PLoS One. 2013;8(8):e70883.

639 53. W.R. L, M.G. K, A.S. H, M.C. L, X. Z, W. Z, et al. Association between preexisting
640 mental illnesses and mortality among medicaid-insured women diagnosed with breast
641 cancer. Soc Sci Med. 2021;270:113643.

642 54. Afshar M, O'Neill T, Patel HRH, De-Santis M, Tanner JR, Evison F, et al. Do Learning
643 Disabilities Affect Testicular Cancer Survival: A National Cohort Study Between 2001
644 and 2015. Eur Urol Oncol. 2020;3(6):773–9.

645 55. Cuypers M, Schalk BWM, Boonman AJN, Naaldenberg J, Leusink GL. Cancer-related
646 mortality among people with intellectual disabilities: A nationwide population-based
647 cohort study. Cancer. 2022;128(6):1267–74.

648 56. Cuypers M, Tobi H, Huijsmans CAA, van Gerwen L, Ten Hove M, van Weel C, et al.
649 Disparities in cancer-related healthcare among people with intellectual disabilities: A
650 population-based cohort study with health insurance claims data. Cancer Med. 2020
651 Sep;9(18):6888–95.

652 57. Robb C, Boulware D, Extermann M, Overcash J. Patterns of care and survival in
653 cancer patients with cognitive impairment. Crit Rev Oncol Hematol. 2010;74(3):218–
654 24.

655 58. Segerlantz M, Axmon A, Ahlström G. End-of-life care among older cancer patients
656 with intellectual disability in comparison with the general population: a national
657 register study. J Intellect Disabil Res. 2020 May;64(5):317–30.

658 59. Segerlantz M, Axmon A, Gagnemo Persson R, Brun E, Ahlström G. Prescription of
659 pain medication among older cancer patients with and without an intellectual
660 disability: a national register study. BMC Cancer. 2019 Nov;19(1):1040.

661 60. S.K. G. Patterns of presentation, diagnosis, and treatment in older patients with colon
662 cancer and comorbid dementia. J Am Geriatr Soc. 2004;52(10):1681–7.

663 61. Iezzoni LI, Ngo LH, Li D, Roetzheim RG, Drews RE, McCarthy EP. Treatment
664 disparities for disabled medicare beneficiaries with stage I non-small cell lung cancer.
665 Arch Phys Med Rehabil. 2008 Apr;89(4):595–601.

666 62. Sato S, Tanimoto A, Yanagimura N, Suzuki C, Takumi Y, Nishiyama A, et al. Multi-
667 institutional survey of cancer disparities in disabled patients in the region of
668 northwestern Japan. Int J Clin Oncol. 2021;26(6):1009–14.

669 63. Shin DW, Park J, Yeob KE, Yoon SJ, Jang S nang, Kim SY, et al. Disparities in
670 prostate cancer diagnosis, treatment, and survival among men with disabilities:
671 Retrospective cohort study in South Korea. Disabil Health J. 2021 Oct 1;14(4).

672 64. Park SM, Son KY, Park JH, Cho B. Disparities in short-term and long-term all-cause
673 mortality among Korean cancer patients with and without preexisting disabilities: a
674 nationwide retrospective cohort study. Support Care Cancer. 2012 May;20(5):963–70.

675 65. Kwon J, Kim SY, Yeob KE, Han HS, Lee KH, Shin DW, et al. Differences in diagnosis,
676 treatment, and survival rate of acute myeloid leukemia with or without disabilities: A
677 national cohort study in the Republic of Korea. Cancer Med. 2020 Aug 1;9(15):5335–
678 44.

679 66. Shin DW, Cho JH, Noh JM, Han H, Han K, Park SH, et al. Disparities in the Diagnosis
680 and Treatment of Lung Cancer among People with Disabilities. Journal of Thoracic
681 Oncology. 2019 Feb 1;14(2):163–75.

682 67. Sathianathen NJ, Fan Y, Jarosek SL, Konety I, Weight CJ, Vinogradov S, et al.
683 Disparities in Bladder Cancer Treatment and Survival Amongst Elderly Patients with a
684 Pre-existing Mental Illness. Eur Urol Focus. 2020 Nov;6(6):1180–7.

685 68. Cuypers M, Tobi H, Huijsmans CAA, Gerwen L, Hove M, Weel C, et al. Disparities in
686 cancer-related healthcare among people with intellectual disabilities: A
687 population-based cohort study with health insurance claims data. Cancer Med. 2020
688 Sep 25;9(18):6888–95.

689 69. Gupta SK, Lamont EB. Patterns of presentation, diagnosis, and treatment in older
690 patients with colon cancer and comorbid dementia. J Am Geriatr Soc.
691 2004;52(10):1681–7.

692 70. D.W. S, J.H. C, J.M. N, H. H, K. H, S.H. P, et al. Disparities in the Diagnosis and
693 Treatment of Lung Cancer among People with Disabilities. Journal of Thoracic
694 Oncology. 2019;14(2):163–75.

695 71. Cuypers M, Tobi H, Huijsmans CAA, van Gerwen L, ten Hove M, van Weel C, et al.
696 Disparities in cancer-related healthcare among people with intellectual disabilities: A
697 population-based cohort study with health insurance claims data. Cancer Med. 2020
698 Sep 1;9(18):6888–95.

699 72. S.E. G, H. P, M. S, L. A, U.-S. A, Gross-Kunkel A. AO - Pfaff HO http://orcid.
700 org/0000 0001 9154 6575. Health disparities among breast cancer patients
701 with/without disabilities in Germany. Disabil Health J. 2020;13(2):100873.

702 73. Andiwijaya FR, Davey C, Bessame K, Ndong A, Kuper H. Disability and Participation
703 in Breast and Cervical Cancer Screening: A Systematic Review and Meta-Analysis.
704 Int J Environ Res Public Health. 2022 Aug 1;19(15).

705 74. Reeves C, Collingridge D. Improving cancer care for people with disabilities. Lancet
706 Oncol. 2022 Apr 1;23(4):446–7.

707 75. Shefer G, Henderson C, Howard LM, Murray J, Thornicroft G. Diagnostic
708 overshadowing and other challenges involved in the diagnostic process of patients
709 with mental illness who present in emergency departments with physical symptoms--a
710 qualitative study. PLoS One. 2014 Nov 1;9(11).

711 76. Stirling M, Anderson A, Ouellette-Kuntz H, Hallet J, Shooshtari S, Kelly C, et al. A
712 scoping review documenting cancer outcomes and inequities for adults living with

713 intellectual and/or developmental disabilities. EUROPEAN JOURNAL OF
714 ONCOLOGY NURSING. 2021;54.

715 77. WHO. Disability and health [Internet]. [cited 2022 Oct 11]. Available from:
716 https://www.who.int/news-room/fact-sheets/detail/disability-and-health

717 78. Hillgrove T, Blyth J, Kiefel-Johnson F, Pryor W. A synthesis of findings from 'rapid
718 assessments' of disability and the COVID-19 pandemic: Implications for response and
719 disability-inclusive data collection. Int J Environ Res Public Health. 2021 Sep
720 1;18(18).

721 79. Shakespeare T, Ndagire F, Seketi QE. Triple jeopardy: disabled people and the
722 COVID-19 pandemic. Lancet. 2021 Apr 10;397(10282):1331–3.

723 80. Banks LM, Davey C, Shakespeare T, Kuper H. Disability-inclusive responses to
724 COVID-19: Lessons learnt from research on social protection in low- and middle-
725 income countries. World Dev. 2021 Jan 1;137.

726 81. Williamson EJ, McDonald HI, Bhaskaran K, Walker AJ, Bacon S, Davy S, et al. Risks
727 of covid-19 hospital admission and death for people with learning disability: population
728 based cohort study using the OpenSAFELY platform. BMJ. 2021 Jul 14;374.

729 82. Bosworth ML, Ayoubkhani D, Nafilyan V, Foubert J, Glickman M, Davey C, et al.
730 Deaths involving COVID-19 by self-reported disability status during the first two waves
731 of the COVID-19 pandemic in England: a retrospective, population-based cohort
732 study. Lancet Public Health. 2021 Nov 1;6(11):e817–25.

733 83. Kuper, Hannah; Heydt P. The Missing Billion: access to health services for 1 billion
734 people with disabilities. London; 2019.

735 84. Shakespeare T, Watson N, Brunner R, Cullingworth J, Hameed S, Scherer N, et al.
736 Disabled people in Britain and the impact of the COVID-19 pandemic. Soc Policy
737 Adm. 2022 Jan 1;56(1):103–17.

738 85. Danos C, Heydt Hannah Kuper London P, Burbach M, Rotenberg S, Seghers F,
739 Miner E, et al. Reimagining health systems that expect, accept and connect 1 billion
740 people with disabilities. 2022 Oct.

741 86. Sakellariou D, Anstey S, Polack S, Rotarou ES, Warren N, Gaze S, et al. Pathways of
742 disability-based discrimination in cancer care. Crit Public Health. 2020;30(5):533–43.

87. Iezzoni LI, Rao SR, Ressalam J, Bolcic-Jankovic D, Agaronnik ND, Donelan K, et al. Physicians' perceptions of people with disability and their health care. Health Aff. 2021 Feb 1;40(2):297–306.

88. Lagu T, Haywood C, Reimold K, DeJong C, Walker Sterling R, Iezzoni LI. 'I Am Not The Doctor For You': Physicians' Attitudes About Caring For People With Disabilities. https://doi.org/101377/hlthaff202200475. 2022 Oct 3;41(10):1387–95.

89. Edwards DJ, Sakellariou D, Anstey S. Barriers to, and facilitators of, access to cancer services and experiences of cancer care for adults with a physical disability: A mixed methods systematic review. Disabil Health J. 2020 Jan 1;13(1).

90. Schwartz JK, Unni E. Inclusion of People with Disabilities in Research to Improve Medication Adherence: A Systematic Review. Patient Prefer Adherence. 2021;15:1671.

91. Younossi Alexandria, Sanhai W, Shah S, Chang C. Enhancing diversity in clinical trials | Deloitte Insights.

92. Meeting report: summary of Day 2 of the 2021 ISMPP European Meeting [Internet]. [cited 2022 Nov 1]. Available from: https://thepublicationplan.com/2021/02/10/meeting-report-summary-of-day-2-of-the-2021-ismpp-european-meeting/

93. Employing disabled people and people with health conditions - GOV.UK [Internet]. [cited 2022 Nov 1]. Available from: https://www.gov.uk/government/publications/employing-disabled-people-and-people-with-health-conditions/employing-disabled-people-and-people-with-health-conditions

94. Agaronnik ND, El-Jawahri A, Lindvall C, Iezzoni LI. Exploring the Process of Cancer Care for Patients With Pre-Existing Mobility Disability. JCO Oncol Pract. 2021 Jan;17(1):e53–61.

95. Marlow NM, Samuels SK, Jo A, Mainous AG. Patient-provider communication quality for persons with disabilities: A cross-sectional analysis of the Health Information National Trends Survey. Disabil Health J. 2019 Oct 1;12(4):732–7.